Concurrent EGFR Tyrosine Kinase Inhibitor Therapy With Radiation Therapy in NSCLC
Posted: Wednesday, November 1, 2017
In patients with epidermal growth factor receptor (EGFR)-mutant, advanced non–small cell lung cancer (NSCLC) who develop systemic or local disease progression due to EGFR tyrosine kinase inhibitor resistance in the front-line setting, continued treatment with an EGFR tyrosine kinase inhibitor therapy along with concurrent radiotherapy seems to be a feasible and effective treatment. These findings were presented by Jianguo Sun, MD, of Xinqiao Hospital, Chongqing, China, at the 2017 American Society for Radiation Oncology (ASTRO) Annual Meeting (Abstract 3723).
The investigators retrospectively examined 50 irradiated lesions from 44 patients with advanced NSCLC who had an active EGFR mutation and were treated with concurrent radiotherapy after local disease progression on EGFR tyrosine kinase inhibitor therapy.
In 31 measurable lesions, the median time to disease progression and progression-free survival were both significantly prolonged after local radiotherapy. For all 50 lesions, the objective response rate and local tumor control rate were 54.0% and 84.0%, respectively, and median overall survival was 26.6 months. There were no serious adverse events before or after radiotherapy.
